HMMC-1: A humanized monoclonal antibody with therapeutic potential against müllerian duct-related carcinomas

Shiro Nozawa, Daisuke Aoki, Katsumi Tsukazaki, Nobuyuki Susumu, Motoko Sakayori, Nao Suzuki, Atsushi Suzuki, Rie Wakita, Makio Mukai, Yuko Egami, Kyoko Kojima-Aikawa, Isao Ishida, Frederic Belot, Ole Hindsgaul, Minoru Fukuda, Michiko N. Fukuda

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. Experimental Design: Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. Results: HMMC-1 is a human IgM monoclonal antibody that reacts positively with müllerian duct-related carcinomas with positive rates of 54.6% against uterine endometrial adenocarcinoma, 76.9% against uterine cervical adenocarcinoma, and 75.0% against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucα1→2Galβ1→ 4GlcNAcβ1→3Galβ1→3GalNAcα1-octyl. Conclusions: These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.

Original languageEnglish
Pages (from-to)7071-7078
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number20
DOIs
Publication statusPublished - 2004 Oct 15

Fingerprint

Antibodies, Monoclonal, Humanized
Carcinoma
Glycosyltransferases
Polysaccharides
Antibodies
Adenocarcinoma
Complementary DNA
Collecting Kidney Tubules
Monoclonal Antibodies
Therapeutics
Antigens
Neoplasms
Uterine Neoplasms
Hybridomas
Endometrial Neoplasms
Endometrium
Oligosaccharides
Cervix Uteri
Transfection
Immunoglobulin M

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HMMC-1 : A humanized monoclonal antibody with therapeutic potential against müllerian duct-related carcinomas. / Nozawa, Shiro; Aoki, Daisuke; Tsukazaki, Katsumi; Susumu, Nobuyuki; Sakayori, Motoko; Suzuki, Nao; Suzuki, Atsushi; Wakita, Rie; Mukai, Makio; Egami, Yuko; Kojima-Aikawa, Kyoko; Ishida, Isao; Belot, Frederic; Hindsgaul, Ole; Fukuda, Minoru; Fukuda, Michiko N.

In: Clinical Cancer Research, Vol. 10, No. 20, 15.10.2004, p. 7071-7078.

Research output: Contribution to journalArticle

Nozawa, S, Aoki, D, Tsukazaki, K, Susumu, N, Sakayori, M, Suzuki, N, Suzuki, A, Wakita, R, Mukai, M, Egami, Y, Kojima-Aikawa, K, Ishida, I, Belot, F, Hindsgaul, O, Fukuda, M & Fukuda, MN 2004, 'HMMC-1: A humanized monoclonal antibody with therapeutic potential against müllerian duct-related carcinomas', Clinical Cancer Research, vol. 10, no. 20, pp. 7071-7078. https://doi.org/10.1158/1078-0432.CCR-04-0802
Nozawa, Shiro ; Aoki, Daisuke ; Tsukazaki, Katsumi ; Susumu, Nobuyuki ; Sakayori, Motoko ; Suzuki, Nao ; Suzuki, Atsushi ; Wakita, Rie ; Mukai, Makio ; Egami, Yuko ; Kojima-Aikawa, Kyoko ; Ishida, Isao ; Belot, Frederic ; Hindsgaul, Ole ; Fukuda, Minoru ; Fukuda, Michiko N. / HMMC-1 : A humanized monoclonal antibody with therapeutic potential against müllerian duct-related carcinomas. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 20. pp. 7071-7078.
@article{07a732f4a80e415d8e1260280955a29c,
title = "HMMC-1: A humanized monoclonal antibody with therapeutic potential against m{\"u}llerian duct-related carcinomas",
abstract = "Purpose: The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. Experimental Design: Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. Results: HMMC-1 is a human IgM monoclonal antibody that reacts positively with m{\"u}llerian duct-related carcinomas with positive rates of 54.6{\%} against uterine endometrial adenocarcinoma, 76.9{\%} against uterine cervical adenocarcinoma, and 75.0{\%} against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucα1→2Galβ1→ 4GlcNAcβ1→3Galβ1→3GalNAcα1-octyl. Conclusions: These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.",
author = "Shiro Nozawa and Daisuke Aoki and Katsumi Tsukazaki and Nobuyuki Susumu and Motoko Sakayori and Nao Suzuki and Atsushi Suzuki and Rie Wakita and Makio Mukai and Yuko Egami and Kyoko Kojima-Aikawa and Isao Ishida and Frederic Belot and Ole Hindsgaul and Minoru Fukuda and Fukuda, {Michiko N.}",
year = "2004",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-04-0802",
language = "English",
volume = "10",
pages = "7071--7078",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - HMMC-1

T2 - A humanized monoclonal antibody with therapeutic potential against müllerian duct-related carcinomas

AU - Nozawa, Shiro

AU - Aoki, Daisuke

AU - Tsukazaki, Katsumi

AU - Susumu, Nobuyuki

AU - Sakayori, Motoko

AU - Suzuki, Nao

AU - Suzuki, Atsushi

AU - Wakita, Rie

AU - Mukai, Makio

AU - Egami, Yuko

AU - Kojima-Aikawa, Kyoko

AU - Ishida, Isao

AU - Belot, Frederic

AU - Hindsgaul, Ole

AU - Fukuda, Minoru

AU - Fukuda, Michiko N.

PY - 2004/10/15

Y1 - 2004/10/15

N2 - Purpose: The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. Experimental Design: Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. Results: HMMC-1 is a human IgM monoclonal antibody that reacts positively with müllerian duct-related carcinomas with positive rates of 54.6% against uterine endometrial adenocarcinoma, 76.9% against uterine cervical adenocarcinoma, and 75.0% against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucα1→2Galβ1→ 4GlcNAcβ1→3Galβ1→3GalNAcα1-octyl. Conclusions: These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.

AB - Purpose: The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. Experimental Design: Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. Results: HMMC-1 is a human IgM monoclonal antibody that reacts positively with müllerian duct-related carcinomas with positive rates of 54.6% against uterine endometrial adenocarcinoma, 76.9% against uterine cervical adenocarcinoma, and 75.0% against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucα1→2Galβ1→ 4GlcNAcβ1→3Galβ1→3GalNAcα1-octyl. Conclusions: These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.

UR - http://www.scopus.com/inward/record.url?scp=6044234744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044234744&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0802

DO - 10.1158/1078-0432.CCR-04-0802

M3 - Article

C2 - 15501987

AN - SCOPUS:6044234744

VL - 10

SP - 7071

EP - 7078

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -